Hypertension in a patient with cancer
Pathophysiology of development of hypertension and proteinuria from VEGFi
Approach to management of hypertension from VEGFi
Denlinger CS, et al. Survivorship: Introduction and definition. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2014; 12:34–45. doi: 10.6004/jnccn.2014.0005
Arima H, et al. Mortality patterns in hypertension. J Hypertens 2011; 29 (Suppl 1):S3–S7. doi: 10.1097/01.hjh.0000410246.59221.b1
Gudsoorkar P, et al. Onco-hypertension: An emerging specialty. Adv Chronic Kidney Dis 2021; 28:477−489.e1. doi: 10.1053/j.ackd.2021.09.011
Ruf R, et al. Onco-hypertension: Overview of hypertension with anti-cancer agents. JON 2021; 5:57–69. doi: 10.1177/23993693211001374
Sufrin G, et al. Hormones in renal cancer. J Urol 1977; 117:433–438. doi: 10.1016/s0022-5347(17)58490-6
Gandini S, et al. Anti-hypertensive drugs and skin cancer risk: A review of the literature and meta-analysis. Crit Rev Oncol Hematol 2018; 122:1–9. doi: 10.1016/j.critrevonc.2017.12.003
Abdel-Qadir H, et al. Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 2017; 53:120–127. doi: 10.1016/j.ctrv.2016.12.002
Lambrechts D, et al. Genetic markers of bevacizumab-induced hypertension. Angiogenesis 2014; 17:685–694. doi: 10.1007/s10456-014-9424-7
Caletti S, et al. Management of VEGF-targeted therapy-induced hypertension. Curr Hypertens Rep 2018; 20:68. doi: 10.1007/s11906-018-0871-1
Ketch T, et al. Four faces of baroreflex failure: Hypertensive crisis, volatile hypertension, orthostatic tachycardia, and malignant vagotonia. Circulation 2002; 105:2518–2523. doi: 10.1161/01.cir.0000017186.52382.f4